文献速递免疫规划传染病防控与疫情报告

在Delta和Omicron变异株优势流行期间,第三剂mRNA疫苗对COVID-19相关急诊和紧急护理就诊及住院的效力——VISION网络,10个州,2021年8月至2022年1月

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-01-21

VISION网络分析了2021年8月26日至2022年1月5日10个州222,772次急诊/紧急护理就诊和87,904例住院的≥18岁成人数据。Delta优势期,第二剂后14-179天、≥180天和第三剂后≥14天对急诊/紧急护理就诊的疫苗效力分别为86%、76%和94%;Omicron优势期分别为52%、38%和82%。对住院的疫苗效力在Delta期分别为90%、81%和94%,Omicron期分别为81%、57%和90%。

要点

  • 第三剂mRNA疫苗在Delta和Omicron优势期均提供最高疫苗效力。
  • Omicron优势期疫苗效力低于Delta优势期,但第三剂后仍保持较高水平。
  • 所有未接种者应尽快接种,所有接受mRNA疫苗基础免疫的成人符合条件时应接种第三剂。

核心结论

  • 在Delta和Omicron优势期,接种第三剂mRNA疫苗的成人对COVID-19相关急诊/紧急护理就诊和住院的疫苗效力估计值最高。
  • 所有未接种者应尽快接种,所有接受mRNA疫苗基础免疫的成人符合条件时应接种第三剂,符合条件者应保持COVID-19疫苗接种最新状态。

研究设计与样本

  • VISION网络分析了2021年8月26日至2022年1月5日10个州≥18岁成人的222,772次急诊和紧急护理就诊及87,904例住院数据。
  • 分析按各研究站点Omicron变异株成为优势株(测序病毒>50%)之前和之后分层。

主要发现

  • Delta优势期,对实验室确诊COVID-19相关急诊/紧急护理就诊的疫苗效力:第二剂后14-179天为86%,第二剂后≥180天为76%,第三剂后≥14天为94%。
  • Omicron优势期,对实验室确诊COVID-19相关急诊/紧急护理就诊的疫苗效力:第二剂后14-179天为52%,第二剂后≥180天为38%,第三剂后≥14天为82%。
  • Delta优势期,对实验室确诊COVID-19相关住院的疫苗效力:第二剂后14-179天为90%,第二剂后≥180天为81%,第三剂后≥14天为94%。
  • Omicron优势期,对实验室确诊COVID-19相关住院的疫苗效力:第二剂后14-179天为81%,第二剂后≥180天为57%,第三剂后≥14天为90%。

关键数值与推荐

  • CDC建议所有≥12岁人群在接种第二剂mRNA疫苗≥5个月后接种第三剂(加强剂),免疫功能低下者接种第三剂基础剂量。

临床怎么用

  • 所有未接种者应尽快接种。
  • 所有接受mRNA疫苗基础免疫的成人符合条件时应接种第三剂,符合条件者应保持COVID-19疫苗接种最新状态。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Estimates of COVID-19 mRNA vaccine effectiveness (VE) have declined in recent months (1,2) because of waning vaccine induced immunity over time,* possible increased immune evasion by SARS-CoV-2 variants (3), or a combination of these and other factors. CDC recommends that all persons aged ≥12 years receive a third dose (booster) of an mRNA vaccine ≥5 months after receipt of the second mRNA vaccine dose and that immunocompromised individuals receive a third primary dose.† A third dose of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine increases neutralizing antibody levels (4), and three recent studies from Israel have shown improved effectiveness of a third dose in preventing COVID-19 associated with infections with the SARS-CoV-2 B.1.617.2 (Delta) variant (5-7). Yet, data are limited on the real-world effectiveness of third doses of COVID-19 mRNA vaccine in the United States, especially since the SARS-CoV-2 B.1.1.529 (Omicron) variant became predominant in mid-December 2021. The VISION Network§ examined VE by analyzing 222,772 encounters from 383 emergency departments (EDs) and urgent care (UC) clinics and 87,904 hospitalizations from 259 hospitals among adults aged ≥18 years across 10 states from August 26, 2021¶ to January 5, 2022. Analyses were stratified by the period before and after the Omicron variant became the predominant strain (>50% of sequenced viruses) at each study site. During the period of Delta predominance across study sites in the United States (August-mid-December 2021), VE against laboratory-confirmed COVID-19-associated ED and UC encounters was 86% 14-179 days after dose 2, 76% ≥180 days after dose 2, and 94% ≥14 days after dose 3. Estimates of VE for the same intervals after vaccination during Omicron variant predominance were 52%, 38%, and 82%, respectively. During the period of Delta variant predominance, VE against laboratory-confirmed COVID-19-associated hospitalizations was 90% 14-179 days after dose 2, 81% ≥180 days after dose 2, and 94% ≥14 days after dose 3. During Omicron variant predominance, VE estimates for the same intervals after vaccination were 81%, 57%, and 90%, respectively. The highest estimates of VE against COVID-19-associated ED and UC encounters or hospitalizations during both Delta- and Omicron-predominant periods were among adults who received a third dose of mRNA vaccine. All unvaccinated persons should get vaccinated as soon as possible. All adults who have received mRNA vaccines during their primary COVID-19 vaccination series should receive a third dose when eligible, and eligible persons should stay up to date with COVID-19 vaccinations.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35085224. doi:10.15585/mmwr.mm7104e3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。